Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Non-Current Debt (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 5 years of Non-Current Debt data on record, last reported at $290.0 million in Q4 2025.

  • For Q4 2025, Non-Current Debt fell 7.94% year-over-year to $290.0 million; the TTM value through Dec 2025 reached $290.0 million, down 7.94%, while the annual FY2025 figure was $290.0 million, 7.94% down from the prior year.
  • Non-Current Debt reached $290.0 million in Q4 2025 per INDV's latest filing, down from $304.0 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $315.0 million in Q4 2024 and bottomed at $237.0 million in Q4 2022.
  • Average Non-Current Debt over 5 years is $280.1 million, with a median of $297.0 million recorded in 2025.
  • Peak YoY movement for Non-Current Debt: surged 32.91% in 2024, then dropped 7.94% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $239.0 million in 2021, then dropped by 0.84% to $237.0 million in 2022, then changed by 0.0% to $237.0 million in 2023, then soared by 32.91% to $315.0 million in 2024, then decreased by 7.94% to $290.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $290.0 million in Q4 2025, $304.0 million in Q3 2025, and $308.0 million in Q2 2025.